Topic: Disease/vaccine specific information
Total results with these characteristics: 916
- Development and Clinical Evaluation of Prevnar 13, a 13-Valent Pneumocococcal CRM197 Conjugate Vaccine
This article, published in the Annals of the New York Academy of Sciences, discusses the development, clinical evaluation, and postlicensure impact of the 13-valent pneumococcal CRM(197) protein conjugate vaccine, PCV13, (Prevnar 13®). ABSTRACT …
Author: Gruber WC, Scott DA, Emini EA
- Development and Implementation of a National Programme for the Management of Severe and Very Severe Pneumonia in Children in Malawi
This article, published in PLoS Medicine, provides an overview of the development and implementation of a national program for the management of severe and very severe childhood pneumonia in Malawi. Based on a successful delivery model used by the …
Author: Enarson PM, Gie R, Enarson DA, Mwansambo C
- Development and Preclinical Evaluation of Safety and Immunogenicity of an Oral ETEC Vaccine Containing Inactivated E. coli Bacteria Overexpressing Colonization Factors CFA/I, CS3, CS5 and CS6 Combined With a Hybrid LT/CT B Subunit Antigen, Administered Alone and Together With dmLT Adjuvant
This article, published in Vaccine, describes the development and preclinical testing of new oral vaccine against enterotoxigenic Escherichia coli (ETEC) administered alone and in combination with an adjuvant. The studies found that oral …
Author: Holmgren J, Bourgeois L, Carlin N, et al.
- Development and Technology Transfer of Haemophilus influenzae type b Conjugate Vaccines for Developing Countries
This article, published in Vaccine, describes the development of a Haemophilus influenzae type b (Hib) conjugate vaccine at the National Institute for Public Health and the Environment/Netherlands Vaccine Institute (RIVM/NVI), and the subsequent …
Author: Beurret M, Hamidi A, Kreeftenberg H
- Development of a Fast-Dissolving Tablet Formulation of a Live Attenuated Enterotoxigenic E. coli Vaccine Candidate
A fast-dissolving tablet (FDT) that could be packaged in a compact stackable blister sheet is a potentially attractive option for formulating oral vaccines, since it would minimally impact the cold chain and could potentially be administered …
Author: Lal M, Priddy S, Bourgeois L, et al.
- Development of a Group A Meningococcal Conjugate Vaccine, MenAfriVac™
Group A meningococcal disease has been an important public health problem in sub-Saharan Africa for over a century. From 2003 to 2009 a monovalent group A conjugate vaccine, MenAfriVac™, was developed through an innovative public/private …
Author: Frasch C, Preziosi M-P, LaForce FM
- Development of a Humanized Monoclonal Antibody (MEDI-493) With Potent In Vitro and In Vivo Activity Against Respiratory Syncytial Virus
This article, published in The Journal of Infectious Diseases, details a preclinical study evaluating the ability of a humanized monoclonal antibody, MEDI-493 (later named palivizumab and marketed at Synagis®), to recognize a conserved …
Author: Johnson S, Oliver C, Prince GA, et al.
- Development of a Low-Dose Challenge Model for Evaluation of Vaccines for Enterotoxigenic E. coli (ETEC) in Volunteers
This presentation from the Vaccines for Enteric Diseases conference provides results from a clinical trial that found the human challenge model currently being used to test vaccines against enterotoxigenic Escherichia coli (ETEC) is utilizing a …
Author: Harro C, DeNearing B, Marcum A, et al.
- Development of Antibodies Against the Putative Proteinase Maturation Protein A in Relation to Pneumococcal Carriage and Otitis Media
Published in FEMS Immunology and Medical Microbiology, this article examines serum anti-pneumococcal proteinase maturation protein A antibodies at 6, 12, 18 and 24 months of age, and showed that the age-related development of antipneumococcal …
Author: Bogaert D, Holmlund E, Lahdenkari M, et al.
- Development of Lactococcal GEM-Based Pneumococcal Vaccines
Published in the journal Vaccine, this article reports on the development of a novel protein-based nasal vaccine against Streptococcus pneumoniae, in which three pneumococcal proteins were displayed on the surface of a non-recombinant, killed …
Author: Audouy S, van Selm S, van Roosmalen M, et al.
- The Development of Live, Attenuated Rotavirus Vaccines: A Manufacturer's Resource Guide
This guide is a compilation of publicly available information about the manufacturing process of rotavirus vaccines, and aims to provide a resource for manufacturers interested in developing and registering an attenuated, oral rotavirus vaccine. …
Author: PATH, GAVI Alliance
- Development of Vaccines Against Meningococcal Disease
This article, published in the Lancet, reviews the currently available vaccines against meningococcal disease, as well as research and development efforts toward the development of additional vaccines against the disease. ABSTRACT …
Author: Jódar L, Feavers IM, Salisbury D, Granoff DM
- Diagnostic and Laboratory Testing Aspects of JE
This slide presentation give an overivew of the diagnostic and laboratory testing aspects of JE and can be apdated to fit your audience.
- Diarrheal Disease: Solutions to Defeat a Global Killer
Diarrheal Disease: Solutions to Defeat a Global Killer presents scientific evidence to support strategies to scale up use of interventions, including safe water, improved sanitation and hygiene, breastfeeding and optimal complementary feeding, …
- Diarrhoea: Why Children Are Still Dying and What Can Be Done
This joint report from the World Health Organization and the United Nations Children's Fund (UNICEF) focuses attention on the prevention and management of diarrheal diseases. It examines the latest available information on the burden of childhood …
Author: World Health Organization, United Nations Children's Fund
- Direct and Indirect Effects of Rotavirus Vaccination Upon Childhood Hospitalizations in 3 US Counties, 2006–2009
This article, published in Clinical Infectious Diseases, is about an active, population-based surveillance for rotavirus gastroenteritis hospitalizations in three United States counties to assess the impact of rotavirus vaccines. The study …
Author: Payne DC, Staat MA, Edwards KM, et al.
- Disease Burden Due to Enterotoxigenic Escherichia coli (ETEC) in the First Two Years of Life in an Urban Community in Bangladesh
Published in Infection and Immunity, a cohort of 321 children were followed from birth up to two years to determine the incidence of enterotoxigenic Escherichia coli (ETEC) in Bangladesh. Children with ETEC diarrhea were underweight and stunted …
Author: Qadri F, Saha A, Ahmed T
- Disease Outbreak News
This web page provides frequently updated information about current disease outbreaks, as well as disease-specific archives of past alerts and links to related resources.
Author: World Health Organization
- Diseases and the Vaccines That Prevent Them
This series of fact sheets describes symptoms of infection as well as the benefits and risk of vaccination for 14 diseases, including hepatitis B, Haemophilus influenzae type b, influenza, pneumococcal disease, polio, and rotavirus. There …
Author: US Centers for Disease Control and Prevention
- Dissociation Between Serum Neutralizing and Glycoprotein Antibody Responses of Infants and Children Who Received Inactivated Respiratory Syncytial Virus Vaccine
In the 1960s a respiratory syncytial virus (RSV) vaccine was evaluated in infants and young children. Vaccinees who received formalin-inactivated RSV during early infancy developed more serious lower-respiratory-tract disease when infected with the …
Author: Murphy BR, Prince GA, Walsh EE, et al.
- Distribution of Rotavirus Genotypes in Europe, 2004-2005: The REVEAL Study
Rotavirus genotypes were identified in several European countries using ELISA tests, and investigators determined that G1–G4 and G9 genotypes were responsible for the majority of cases. Citing these results, the authors suggest that rotavirus …
Author: Van Damme P, Giaquinto C, Maxwell M, Todd P, Van der Wielen M
- Distributional Impact of Rotavirus Vaccination in 25 GAVI Countries: Estimating Disparities in Benefits and Cost-Effectiveness
This article, published in Vaccine, reports on an analysis that combines the results of a country-level model of rotavirus vaccination published elsewhere with data from Demographic and Health Surveys on within-country patterns of vaccine coverage …
Author: Rheingans R, Atherly D, Anderson J
- DNA Vaccines Expressing Pneumococcal Surface Protein A (PspA) Elicit Protection Levels Comparable to Recombinant Protein
This article, published in the Journal of Medical Microbiology, provide results that show that DNA vaccines expressing PspA are able to elicit protection levels comparable to recombinant protein, even though total anti-PspA IgG response is …
Author: Ferreira DM, Miyaji EN, Oliveira MLS, et al.
- A Dose-Escalation Safety and Immunogenicity Study of Live Attenuated Oral Rotavirus Vaccine 116E in Infants: A Randomized, Double-Blind, Placebo-Controlled Trial
This study, published in the Journal of Infectious Diseases, tested the neonatal rotavirus candidate vaccine 116E in a double-blind, placebo-controlled dose-escalation trial in India. Two doses of the Vero cell-adapted vaccine were evaluated in …
Author: Bhandari N, Sharma P, Taneja S, et al.
- Duration of Protection of Pentavalent Rotavirus Vaccination in Nicaragua
This article, published in Pediatrics, summarizes a case-control study conducted at four hospitals in Nicaragua to evaluate the duration of protection after rotavirus vaccination among eligible infants. The pentavalent rotavirus vaccine …
Author: Patel M, Pedreira C, De Oliveira LH, et al.